Goldstein: Expect More Litigation After Myriad

June 13 (Bloomberg Law) -- Tom Goldstein, partner at Goldstein & Russell, PC and founder of SCOTUSblog, talks with Bloomberg Law's Lee Pacchia about the United States Supreme Court's decision in the Association for Molecular Pathology v. Myriad Genetics, Inc. case. At issue was whether patents may be granted on parts of the human body. He also explores whether Justice Scalia's concurrence raises doubts whether he believes in molecular biology, and where patent litigation will head in the wake of the decision. Bloomberg Law is a sponsor of SCOTUSblog.

S&P Ratings Chief Sees U.K. Heading for Hard Brexit
44:41 - S&P Global Ratings Chief Rating Officer Moritz Kraemer discusses his outlook for Brexit negotiations. He speaks on "Bloomberg Daybreak: Europe." (Source: Bloomberg)
  • How Brexit May Impact Downside Risks for Equities
  • Parsing the Impact of Tax Cuts on Saudi Aramco
  • Woodside Petroleum CEO Sees Oil Between $45 to $60